Plymouth Meeting, Pa. —May 28, 2018 — Braeburn announces the resubmission of the New Drug Application (NDA) for CAM2038, an investigational buprenorphine flexible-dose weekly and monthly depot injection for the treatment of opioid use disorder…Original Article
Braeburn Resubmits New Drug Application for CAM2038 for Opioid Use Disorder
